ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 10

Roles of Histone Acetyltransferases CBP/p300 and Transcriptional Factor RORα/REV-ERBα Against TNFα-induced CCL2 Expression in RA-FLSs

Ikumi Okumura1, Kohsuke Yoshida 1, Kenta Kaneshiro 2, Koto Uchida 3, Arisa Yaekura 4, Yuto Oketani 5, Kanta Morii 1, Koji Tateishi 6, Yasuhiro Terashima 6, Yoshiko Kawasaki 7, Nao Shibanuma 7, Yoshitada Sakai 8 and Akira Hashiramoto 1, 1Kobe University Graduate School of Health Sciences, Kobe, Hyogo, Japan, 2Kobe University Graduate School of Health Sciences, Osaka, Osaka, Japan, 3Kobe University Graduate School of Health Sciences, Okayama, Okayama, Japan, 4Kobe University Graduate School of Health Sciences, Kawanishi, Hyogo, Japan, 5Kobe University Graduate School of Health Sciences, Himeji, Hyogo, Japan, 6Kohnan Kakogawa Hospital, Kakogawa, Hyogo, Japan, 7Kobe Kaisei Hospital, Kobe, Hyogo, Japan, 8Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: chemokines and Cell Migration

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: Cytokines & Cell Trafficking Poster

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: We have reported that TNFα induced expressions of clock gene Bmal1 by up-regulating transcriptional activator RORα and down-regulating repressor REV-ERBα in RA fibroblast-like synoviocytes (RA-FLSs), and that histone acetyltransferases CREB binding protein (CBP) and p300 were involved in this process. A chemokine CCL2, associated with cell proliferation and migration of RA-FLSs, is regulated by RORα and REV-ERBα as well as Bmal1. In this study, we investigate the relation between RORα/REV-ERBα, histone acetyltransferases and TNFα-induced CCL2 expression in RA-FLSs.

Methods: To examine the effect of RORα antagonist SR1001 and REV-ERBα agonist GSK4112 on TNFα-induced CCL2 expression, primary cultured RA-FLSs were treated with SR1001 (20μM) and/or GSK4112 (20μM) in the presence of TNFα (10ng/ml) for 24h.

Next, to clarify the role of histone acetyltransferases on TNFα-induced CCL2, cells were incubated with p300/CBP inhibitor C646 or transfected with both p300 and CBP small interfering RNA (siRNA) before stimulation with TNF-α. Thereafter, intracellular CCL2 mRNA and culture supernatant CCL2 were analyzed by qPCR and ELISA, respectively.

To examine the effect of C646 on TNFα-induced cell migration of RA-FLSs, wound healing assay and immunofluorescence observation were performed by using two different culture supernatant of TNFα-stimulation; DMSO pre-treated control and C646 pre-treated one.

Results: TNFα-induced CCL2 expression was strongly inhibited by simultaneous treatment with both SR1001 and GSK4112, as compared with solo treatment of each agents. Further, CCL2 expressions were also suppressed by pretreatment with C646 and silencing of both Cbp and p300 genes. C646 significantly inhibited both TNFα-induced cell migration and reorganization of the actin cytoskeleton as compared to those with DMSO control (Figure 1).

Conclusion: We newly found that TNFα induced expression of CCL2 through RORα and REV-ERBα, which was associated with CBP/p300 in RA-FLSs, in the same manner as Bmal1.

Results propose these molecules as novel therapeutic targets of RA.


Figure 1

Figure 1. TNFα induced reorganization of the actin cytoskeleton in RA-FLSs -A and B-, while C646 significantly inhibited that -C-.


Disclosure: I. Okumura, None; K. Yoshida, None; K. Kaneshiro, None; K. Uchida, None; A. Yaekura, None; Y. Oketani, None; K. Morii, None; K. Tateishi, None; Y. Terashima, None; Y. Kawasaki, None; N. Shibanuma, None; Y. Sakai, None; A. Hashiramoto, None.

To cite this abstract in AMA style:

Okumura I, Yoshida K, Kaneshiro K, Uchida K, Yaekura A, Oketani Y, Morii K, Tateishi K, Terashima Y, Kawasaki Y, Shibanuma N, Sakai Y, Hashiramoto A. Roles of Histone Acetyltransferases CBP/p300 and Transcriptional Factor RORα/REV-ERBα Against TNFα-induced CCL2 Expression in RA-FLSs [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/roles-of-histone-acetyltransferases-cbp-p300-and-transcriptional-factor-ror%ce%b1-rev-erb%ce%b1-against-tnf%ce%b1-induced-ccl2-expression-in-ra-flss/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/roles-of-histone-acetyltransferases-cbp-p300-and-transcriptional-factor-ror%ce%b1-rev-erb%ce%b1-against-tnf%ce%b1-induced-ccl2-expression-in-ra-flss/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology